Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae
- PMID: 24777907
- DOI: 10.1093/jac/dku118
Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae
Abstract
Objectives: Antimicrobial resistance in Neisseria gonorrhoeae is a major public health concern globally. We report the first verified treatment failure of gonorrhoea with 2 g of azithromycin (extended-release formulation) in Japan and characteristics of the corresponding N. gonorrhoeae isolates.
Methods: Pre- and post-treatment isolates (n = 4) were investigated by Etest for antimicrobial susceptibility. The isolates were examined for molecular epidemiology by multilocus sequence typing (MLST), N. gonorrhoeae multi-antigen sequence typing (NG-MAST) and multiple-locus variable-number tandem repeat analysis (MLVA), and for the presence of azithromycin resistance determinants (23S rRNA gene mutations, erm genes and mtrR mutations).
Results: All isolates were resistant to azithromycin (MIC 4 mg/L) and ciprofloxacin, but remained susceptible to cefixime, ceftriaxone and spectinomycin. All isolates were assigned to MLST ST1901 and NG-MAST ST1407 and three of four isolates possessed MLVA profile 8-3-21-16-1. All isolates contained the previously described C2599T mutation (N. gonorrhoeae numbering) in all four 23S rRNA alleles and the previously described single-nucleotide (A) deletion in the mtrR promoter region.
Conclusions: This verified treatment failure occurred in a patient infected with an MLST ST1901/NG-MAST ST1407 strain of N. gonorrhoeae. While this international strain commonly shows resistance or decreased susceptibility to multiple antimicrobials, including extended-spectrum cephalosporins, the strain reported here remained fully susceptible to the latter antimicrobials. Hence, two subtypes of azithromycin-resistant gonococcal MLST ST1901/NG-MAST ST1407 appear to have evolved and to be circulating in Japan. Azithromycin should not be recommended as a single antimicrobial for first-line empirical treatment of gonorrhoea.
Keywords: 23S rRNA; N. gonorrhoeae; N. gonorrhoeae multi-antigen sequence typing; NG-MAST; antimicrobial resistance; test of cure.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Hefei (2014-2015): genetic characteristics of antimicrobial resistance.BMC Infect Dis. 2017 May 25;17(1):366. doi: 10.1186/s12879-017-2472-z. BMC Infect Dis. 2017. PMID: 28545411 Free PMC article.
-
Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan.BMC Infect Dis. 2015 Sep 17;15:378. doi: 10.1186/s12879-015-1110-x. BMC Infect Dis. 2015. PMID: 26381611 Free PMC article.
-
Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure.J Antimicrob Chemother. 2013 Jun;68(6):1267-70. doi: 10.1093/jac/dkt034. Epub 2013 Feb 14. J Antimicrob Chemother. 2013. PMID: 23416957
-
Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.Med Microbiol Immunol. 2020 Apr;209(2):95-108. doi: 10.1007/s00430-019-00651-4. Epub 2019 Dec 4. Med Microbiol Immunol. 2020. PMID: 31802195 Free PMC article. Review.
-
Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.BMC Infect Dis. 2015 Aug 21;15:364. doi: 10.1186/s12879-015-1029-2. BMC Infect Dis. 2015. PMID: 26293005 Free PMC article. Review.
Cited by
-
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.Sci Rep. 2015 Jul 14;5:11827. doi: 10.1038/srep11827. Sci Rep. 2015. PMID: 26168713 Free PMC article. Clinical Trial.
-
Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility.Sex Health. 2019 Sep;16(5):488-499. doi: 10.1071/SH18227. Sex Health. 2019. PMID: 31230613 Free PMC article.
-
In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates.Antimicrob Agents Chemother. 2015 Mar;59(3):1605-11. doi: 10.1128/AAC.04536-14. Epub 2014 Dec 29. Antimicrob Agents Chemother. 2015. PMID: 25547354 Free PMC article.
-
Developing a model to predict individualised treatment for gonorrhoea: a modelling study.BMJ Open. 2021 Jun 25;11(6):e042893. doi: 10.1136/bmjopen-2020-042893. BMJ Open. 2021. PMID: 34172543 Free PMC article.
-
Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019.BMC Infect Dis. 2022 Jun 7;22(1):524. doi: 10.1186/s12879-022-07509-w. BMC Infect Dis. 2022. PMID: 35672671 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical